Peer-reviewed veterinary case report
Synthetic microRNA-205 injected into dog melanoma tumors reduced
By Yoshikawa, Ryutaro et al.·Published in Veterinary and comparative oncology·2019·Joint Department of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Synthetic microRNA-205 exhibited tumour suppression in spontaneous canine malignant melanoma by intratumoral injection.
- Species:
- dog
Plain-English summary
A group of ten dogs with malignant melanoma (a type of skin cancer) received injections of a synthetic microRNA called miR-205BP/S3 directly into their tumors. The treatment showed promising results, with five dogs achieving complete remission and three showing stable disease, meaning their cancer did not worsen. Importantly, there were no side effects or changes in blood parameters noted during the treatment. This suggests that miR-205BP/S3 could be a safe and effective option for treating melanoma in dogs.
People also search for: dog skin cancer treatment · melanoma in dogs · miRNA therapy for canine cancer · dog tumor injection treatment
Abstract
MicroRNAs (miRNA) are small, noncoding RNA molecules consisting of 18 to 25 nucleotides. Malignant melanomas (MMs) are one of the most common malignancies in both dogs and humans. We previously reported that chemically modified synthetic miRNA-205 (miR-205BP/S3) inhibits melanoma growth in vitro and in vivo. The present study aimed to evaluate the efficacy of intratumoral administration of synthetic miR-205 for spontaneous CMMs and to evaluate its potential as systemic therapy. Ten dogs with various stages of MM were treated with miR-205BP/S3 injected into tumours. Adverse effects (AEs) were assessed in accordance with the Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v1.1 guidelines. Five cases attained complete remission (CR), three attained stable disease (SD), and two cases displayed characteristics of progressive disease (PD). In all cases, no changes were observed in the blood parameters upon miRNA administration, and miR-205BP/S3 administration did not yield any side effects. The present results suggest that intratumoral administration of miR-205BP/S3 is a potentially applicable treatment for canine melanoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31020761/